MENU
LFSC
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

LFSC stock forecast, quote, news & analysis

The investment seeks long-term capital appreciation... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for LFSC with price predictions
Nov 10, 2026

Momentum Indicator for LFSC turns positive, indicating new upward trend

LFSC saw its Momentum Indicator move above the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator turned positive. In 29 of the 32 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LFSC's RSI Oscillator exited the oversold zone, 5 of 7 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.

The Moving Average Convergence Divergence (MACD) for LFSC just turned positive on October 21, 2026. Looking at past instances where LFSC's MACD turned positive, the stock continued to rise in 16 of 18 cases over the following month. The odds of a continued upward trend are 89%.

LFSC moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for LFSC crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 4 of 4 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +8.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where LFSC advanced for three days, in 104 of 118 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LFSC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

LFSC broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for LFSC entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Guardant Health (NASDAQ:GH), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

The investment seeks long-term capital appreciation. The fund is an actively managed exchange-traded fund (“ETF”) and invests primarily in equity securities of life science companies selected by Emerald Mutual Fund Advisers Trust, the fund’s investment sub-adviser, under the supervision of the adviser. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities issued by life science companies demonstrating innovation.

Market Cap

The average market capitalization across the F/M Emerald Life Sciences Innovation ETF (LFSC) ETF is 5.59B. The market cap for tickers in the group ranges from 217.2M to 24.11B. UTHR holds the highest valuation in this group at 24.11B. The lowest valued company is KRRO at 217.2M.

High and low price notable news

The average weekly price growth across all stocks in the F/M Emerald Life Sciences Innovation ETF (LFSC) ETF was 31%. For the same ETF, the average monthly price growth was 71%, and the average quarterly price growth was 317%. VCEL experienced the highest price growth at 44%, while GH experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the F/M Emerald Life Sciences Innovation ETF (LFSC) ETF was -9%. For the same stocks of the ETF, the average monthly volume growth was 41% and the average quarterly volume growth was -34%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 53
Price Growth Rating: 50
SMR Rating: 84
Profit Risk Rating: 77
Seasonality Score: 28 (-100 ... +100)
Momentum Indicator for LFSC turns positive, indicating new upward trend